Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort - PubMed (original) (raw)
. 2008 May 15;14(10):2988-93.
doi: 10.1158/1078-0432.CCR-07-4723.
Dennis C Sgroi, Paula D Ryan, Tako J Bruinsma, Annuska M Glas, Anitha Male, Sonika Dahiya, Karleen Habin, Rene Bernards, Daniel A Haber, Laura J Van't Veer, Sridhar Ramaswamy
Affiliations
- PMID: 18483364
- PMCID: PMC3089800
- DOI: 10.1158/1078-0432.CCR-07-4723
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort
Ben S Wittner et al. Clin Cancer Res. 2008.
Abstract
Purpose: Most node-negative breast cancer patients are older and postmenopausal and are increasingly being offered adjuvant chemotherapy despite their low overall risk of distant relapse. A molecular diagnostic test with high negative predictive value (NPV) for distant metastasis in this subgroup would spare many older breast cancer patients adjuvant treatment.
Experimental design: We determined the NPV and positive predictive value of the MammaPrint assay in breast cancer patients who were consecutively diagnosed and treated at the Massachusetts General Hospital between 1985 and 1997. Primary tumors from 100 patients with node-negative, invasive breast cancer (median age, 62.5 years; median follow-up, 11.3 years) were subjected to MammaPrint analysis and classified as being at either low or high risk for distant metastasis.
Results: The MammaPrint 70-gene signature displayed excellent NPV as in previous studies, correctly identifying 100% of women at low risk for distant metastases at 5 years. However, this assay had a lower positive predictive value (12% at 5 years) than previously observed.
Conclusions: The MammaPrint assay was originally designed to identify younger breast cancer patients at low risk for distant metastasis, who might consequently be spared systemic treatment. We show here that the same signature has a very high NPV for distant recurrence after adjuvant treatment in older breast cancer patients.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
L.J.Van’t Veer, A.M. Glass, and T. Bruinsma are employed by Agendia BV. L.J. Van’t Veer has an ownership interest in MammaPrint. L.J.Van’tVeer and R. Bernards are named inventors on a patent to use microarray technology to ascertain breast cancer prognosis and hold equity interests in Agendia BV.
Figures
Fig. 1
Overall clinical outcome of node-negative MGH versus NKI patients. Kaplan-Meier analysis of time to metastasis as a first event for the MGH and node-negative NKI cohorts. Green, MGH; black, NKI node negative; thin lines, 95% confidence interval (95% CI); black lines, previously published data (11).
Fig. 2
Molecular classification of MGH patients. Kaplan-Meier analysis of time to metastasis as a first event for the MGH cohort based on classification with the 70-gene signature. Red, MammaPrint high risk; blue, MammaPrint low risk; thin lines, 95% CI.
Fig. 3
Classification of MGH patients using Adjuvant! Online compared with MammaPrint. Adjuvant! Online – based relapse risk for individual patients classified as MammaPrint lowor high risk for (A) all 100 patients, (B) strictly considering 10-y distant metastasis-free survival. Solid square, patient with distant metastasis as a first event; circle, patient without distant metastasis as a first event; + in circle, patient identified as low risk by MammaPrint beyond Adjuvant! Online – based classification; horizontal line, threshold that simultaneously maximizes the number of patients classified as low risk while maintaining a NPV of 100%.
Similar articles
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. Cardoso F, et al. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. N Engl J Med. 2016. PMID: 27557300 Clinical Trial. - Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, van Lienen E, Inaji H, Van't Veer LJ, Kato K. Ishitobi M, et al. Jpn J Clin Oncol. 2010 Jun;40(6):508-12. doi: 10.1093/jjco/hyp195. Epub 2010 Jan 27. Jpn J Clin Oncol. 2010. PMID: 20110242 - 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. Piccart M, et al. Lancet Oncol. 2021 Apr;22(4):476-488. doi: 10.1016/S1470-2045(21)00007-3. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721561 Clinical Trial. - MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.
Slodkowska EA, Ross JS. Slodkowska EA, et al. Expert Rev Mol Diagn. 2009 Jul;9(5):417-22. doi: 10.1586/erm.09.32. Expert Rev Mol Diagn. 2009. PMID: 19580427 Review. - Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM. Dobbe E, et al. Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. doi: 10.2146/ajhp060352. Am J Health Syst Pharm. 2008. PMID: 18159035 Review.
Cited by
- Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Coombes RC, Angelou C, Al-Khalili Z, Hart W, Francescatti D, Wright N, Ellis I, Green A, Rakha E, Shousha S, Amrania H, Phillips CC, Palmieri C. Coombes RC, et al. Breast Cancer Res Treat. 2024 Jun;205(2):349-358. doi: 10.1007/s10549-023-07229-y. Epub 2024 Jan 20. Breast Cancer Res Treat. 2024. PMID: 38244167 Free PMC article. - Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.
Xulu KR, Nweke EE, Augustine TN. Xulu KR, et al. Front Genet. 2023 Aug 17;14:1087432. doi: 10.3389/fgene.2023.1087432. eCollection 2023. Front Genet. 2023. PMID: 37662839 Free PMC article. Review. - Using Classification and K-means Methods to Predict Breast Cancer Recurrence in Gene Expression Data.
Sehhati M, Tabatabaiefar MA, Gholami AH, Sattari M. Sehhati M, et al. J Med Signals Sens. 2022 May 12;12(2):122-126. doi: 10.4103/jmss.jmss_117_21. eCollection 2022 Apr-Jun. J Med Signals Sens. 2022. PMID: 35755980 Free PMC article. - Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review.
Glaab E, Rauschenberger A, Banzi R, Gerardi C, Garcia P, Demotes J. Glaab E, et al. BMJ Open. 2021 Dec 6;11(12):e053674. doi: 10.1136/bmjopen-2021-053674. BMJ Open. 2021. PMID: 34873011 Free PMC article. Review. - DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer.
Lei L, Wang XJ, Mo YY, Cheng SH, Zhou Y. Lei L, et al. Front Oncol. 2020 May 25;10:783. doi: 10.3389/fonc.2020.00783. eCollection 2020. Front Oncol. 2020. PMID: 32528885 Free PMC article.
References
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. - PubMed
- Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol; Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer; 2001. pp. 3817–3827. - PubMed
- Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer; J Natl Cancer Inst; 2001. [November 1–3, 2000]. pp. 979–989. - PubMed
- Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol. 2001;28:53–67. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical